摘要
目的:评价中西药2种方案治疗慢性心力衰竭(CHF)的经济学效果。方法:208例CHF患者按中、西药不同治疗方案分为卡维地洛组与稳心颗粒组,在接受常规治疗(地高辛+螺内酯+福辛普利钠)的基础上,分别辅以卡维地洛、稳心颗粒治疗26周,观察2组疗效并进行成本-效果分析。结果:卡维地洛组与稳心颗粒组的有效率分别为91.5%、53.3%(P<0.05),成本分别为4294.64、4129.02元,成本-效果比分别为4693.60、7746.75,卡维地洛组相对于稳心颗粒组的增量成本-效果比为433.56。结论:相对于稳心颗粒联合常规治疗,卡维地洛联合常规治疗具有明显的药物经济学优势。
OBJECTIVE： To evaluate the pharmacoeconomic effect of TCM therapeutic scheme vs. western medicine therapeutic scheme for chronic heart failure （CHF）. METHODS： 208 CHF patients were randomly divided into Carvedilol group and Wenxin granules group according to therapeutic scheme. Both groups were given conventional therapy including digoxin, spironolactone and fosinopril sodium. They were additionally treated with Carvedilol or Wenxin granules respectively for 26 weeks. Therapeutic efficacies of two groups were observed to analyze the cost-effectiveness of them. RESULTS： The effective rates were 91.5% for Carvedilol group and 53.3% for Wenxin granules group （P-〈0.05）. The costs of two groups were 4 294.64 yuan and 4 129.02 yuan. The cost-effectiveness ratios were 4 693.60 and 7 746.75, respectively. The incremental cost-effectiveness ratio of Carvedilol group was 433.56 yuan, compared with Wenxin granules group. CONCLUSION： Compared with Wenxin granules combined with conventional therapy, Carvedilol combined with conventional therapy has pharmacoeconomical advantages in the treatment of CHF.
出处
《中国药房》
CAS
CSCD
北大核心
2011年第34期3174-3176,共3页
China Pharmacy
关键词
慢性心力衰竭
卡维地洛
稳心颗粒
成本.效果分析
Chronic heart failure
Carvedilol
Wenxin granules
Cost-effectiveness analysis
